Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Meta Expands AI Training With Employee Activity Tracking Tools 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
REDWOOD CITY, Calif., March 01, 2016 -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the 36th Annual Cowen Health Care Conference on March 8, 2016 at 8:00 a.m. ET.
To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's website at http://investor.relypsa.com/events.cfm.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company’s first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa’s rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Alex Dobbin
Associate Director, Investor Relations
650-421-9687
[email protected]
